Release date: 2014-08-21
Deloitte predicts that there will be 100 million eVisits users worldwide in 2014. They will use the new technology platform as a medium to enjoy medical services without leaving home. Compared to an individual visiting a doctor directly, eVisits can save more than $5 billion, which is four times that of 2012. However, the largest market for eVisits is in North America, which is expected to reach 75 million users in 2014. In the United States and Canada, 600 million patient visits to clinics each year, and about half of the problems can be solved by eVisits. To explain this term, Dr.2 believes that: eVisits mentioned by Deloitte includes some remote consultations, standardized consultation for grading visits, implementation of clinical pathways, and some “light consultations†and daily consultations, which are technology-driven. Innovation in medical models.
For decades, due to advances in technology, there have been various alternative forms of telemedicine that have come to visit doctors. For example: the telephone in the 1920s, the remote communication telephone in the 1970s, and the connection system of the Internet as the terminal of the public information network in the past 20 years, and the most popular in the near future is the rapid spread of mobile Internet hardware and software. Cost savings and large-scale applications provide the foundation.
Dr.2 found that Deloitte repeatedly mentioned that 2014 should be a turning point in eVisits use, mainly due to the reduction of medical expenses and the continuous pressure to improve medical services, as well as the improvement of related technologies: such as the popularity of computers, mobile phones and network services. . As elderly patients visiting doctors, they are more willing to use technology products and large-scale use of devices combined with the mobile Internet. Advances in technology have made it possible to automate the background of eVisits, and the popularity of hospital and clinic fiber networks has provided eVisits with more data-intensive applications, such as transmitting brain scan images for tele-strok applications.
A common misconception about eVisits is that it is a video conference where the patient sits in front of the computer, connects to the doctor, and then sticks his tongue at the camera on the network and says "ah." This type of eVisits is only a small part of this market, but it only slightly reduces the cost of direct visits to doctors. Most eVisits products are more versatile and focus on obtaining patient information through forms, questionnaires and photos. Rather than communicating directly with the doctor. For example, in patients with certain diseases, such as sinusitis, strep throat, allergies, cystitis, or acne, they can fill out a form online, receive a diagnosis, and receive a prescription if needed.
Each year, US patients directly visit doctors' clinics, emergency departments, and hospitals (providing outpatient services) with 1.2 billion, which is equivalent to an average of 3.3 visits per US citizen. More than half of the times are visits to junior doctors. More than 110 million visits to doctors due to continued medication, cough, stomachache, sore throat, earache and rash, and these types of visits can be screened and resolved via eVisits.
The target market of eVisits in developed countries is expected to reach 50 billion to 60 billion US dollars. The calculation process is as follows: Every year, EU citizens visit doctors 6.3 times per person. Suppose the EU and North American habits are similar, that is, about half of them visit junior doctors, so we reasonably infer that they visit primary doctors about 3-4 times a year. In developed countries including Europe, the United States and Japan, there are about 1 billion people, that is to say, the target market for direct visits to doctors in developed countries is close to 3.5 billion times a year. The cost of direct visits to doctors varies significantly, with $11 in Spain, $40 in Germany, and $89 in the United States. We assume that in developed countries, the cost per direct visit to a doctor is $50, and the total annual cost of direct visits to doctors is $175 billion. Of course, eVisits does not solve all the problems faced by junior doctors, but even among them, even 30%-40% can be solved by eVisits, which means that the eVisits target market still has $50-60 billion. Note that Dr.2 disagrees with Deloitte's reasoning here. Since eVisits can reduce the total cost accordingly, it is an alternative innovation, so even if the corresponding target market is indeed equivalent to $500-60 billion, the actual amount is Far less than the above amount, it is estimated that it is only half at most. And the savings will be redistributed, which is also a "profit-driven" development of eVisits.
eVisits can also be a branch of the telemedicine market, which also includes expert advice, remote monitoring, alerts/notifications, and other smaller markets.
The business environment of 2014 was a driving factor for the significant increase in the number and value of eVisits. The best solution for global health care is to reduce disease costs by focusing on prevention and early intervention, and to reduce medical costs through continuous integration of information technology. Although Deloitte’s report did not mention it, Dr.2 combined with Obama’s comprehensive medical reform in the United States, one of the core of the medical reform is to control costs, and one core is how to make medical services more convenient and faster to cover low income. crowd. At the same time, the global shortage of physician resources and the widespread medical insurance for uninsured people have increased the focus on eVisits technology. eVisits can reduce traffic time and cost, improve convenience, and provide rapid treatment for patients, so the market demand is very strong. On the other hand, the convenience of eVisits may increase the number of consultations, which may also offset the cost savings of some eVisits. Dr.2 strongly agrees with this because we need to use a dynamic vision when analyzing the industry, and expect many changes that come with the ecological evolution.
North America is perhaps the number one in the global eVisits service. A variety of products and services are growing significantly in the US market, and these services are consistent with the clinical diagnostic results of direct visits to doctors but reduce costs. Moreover, US technology suppliers have partnered with governments and insurance companies. The use of eVisits in Canada is also growing at a rate of 50% per year. By using eVisits, the waiting time for primary care is greatly reduced, and the waiting time for some professional dermatological consultations is also reduced by 6-8 months.
Outside of North America, eVisits usage varies widely. Both the UK and Denmark offer some eVisits services, but such penetration in the Asia Pacific region is limited. However, the pilot project in Indonesia has been successful. It is worth noting that early adopters in Kenya, due to the extreme lack of their physician resources and the difficulty of visiting doctors, made them urgently seeking alternatives to medical delivery systems. The Mashavu Networked Medical Solutions Pilot Program demonstrates that eVisits can be successfully deployed in countries outside the developed regions.
Although more complex diagnoses and treatments still need to be done face-to-face, basic diagnosis, supplementation of prescription drugs, and even professional services such as dermatology can be achieved at the ubiquitous terminal or in a comfortable and private home.
As developed countries validate and apply eVisits, developing countries deploy the necessary infrastructure to provide primary care and diagnostic services to a large population that is now inaccessible. Although eVisits was originally designed to save hundreds of millions of dollars, it may save thousands of lives over time.
in conclusion:
Outside the health care sector, the most obvious beneficiaries are the technology and telecommunications industries. As the market evolves, they will see the growing demand for data capacity, data service quality, high-speed broadband and machine connectivity, and wired or wireless networks for wired and wireless networks. Equipment manufacturers may also be the beneficiaries, and with the accelerated development of mobile healthcare in 2014 and beyond, there may be new growth opportunities for devices, peripherals and apps. A report on a compound annual growth rate of 66% between 2012 and 2017 confirms that “medical applications†is one of the key drivers of this traffic growth.
Public and private institutions should continue to promote policy reforms that do not have to pay eVisits suppliers. This payment reform has been implemented in areas where telemedicine projects are mature. Ontario, Canada has recently added a public insurance payment code to allow physicians to pay for “e-consultationâ€, while the Australian and French government health authorities have changed their funding policies to actively support and promote the development of eVisits. From an individual perspective, payers in the United States, especially those who have proliferated under the medical reform, are extremely interested in the eVisits project. Although so far, only 18 states in the United States have passed laws that require private individuals to reimburse telemedicine expenses.
Educational organizations, research institutions and NGOs have the ability to accelerate the use of eVisits through pilot research and comprehensive assessments. The North American organization dedicated to telemedicine advancement, the Ontario Telemedicine Network and the American Telemedicine Association, will play a key role in promoting the potential of eVisits in these channels.
Governments with successful eVisits solutions will share his insights into the impact of effective incentives and the legal and technical barriers to adoption of eVisits. Denmark has provided eVisits services for many years and is piloting areas such as remote psychiatric treatment. These pilots will be tested on a large scale, and in order to validate and build the solution, other countries can adjust the response of their respective eVisits services.
Physicians, hospitals, and other health care providers should consider what investments they need to make patient access, electronic medical records, security, and privacy systems benefit from the efficient service and technology improvements eVisits provides. Similarly, technology providers should simulate telemedicine systems where eVisits may accelerate development, and then decide how companies should be involved in the future of telemedicine, where patients themselves are part of a healthcare management solution that uses sensors, devices and Communication systems to monitor treatment and health.
Whether it is the eVisits service system in progress, human resources training, familiarity with computer use and telemedicine, or the overall organization's readiness, these indicate that the promotion of this service is “impossibleâ€. Support from the government and other partners, such as employers, who benefit from reduced employee time to see a doctor, is also important.
Introducing doctors to the multiple benefits of eVisits is also one of the keys to universal adoption. Media reports only tend to focus on the benefits of eVisits for patients, insurers/payers, however, in order to stabilize eVisits, physicians also need to improve on the technology infrastructure. Although some physicians believe that eVisits is not human and lacks interpersonal interaction, many doctors see this as an opportunity to increase the quality and efficiency of simple cases and to have more time to study more complex and difficult cases. Similarly, as long as the responsibility for network diagnostics is handled properly, physicians can enjoy many of the other features of eVisits, including sharing clinical data and information with colleagues through the network, helping more remote patients in the shortest time, and the potential for flexible scheduling.
In summary, Dr. 2 believes that the stone of his mountain can attack jade. The deployment and technological evolution of eVisits in developed countries will also promote the development of corresponding industries in our country. At present, the most pure domestic and benchmarking company is “Spring Rain Doctorâ€. I think this is why although it continues to make huge losses, it still wins the favor of huge amount of financing. Of course, VCs are indeed “gamblingâ€, there is no risk, what is it? Venture capital, but they bet the whole industry!
Source: i dark horse
Disposable Reinforced Surgical Gown
CE Certified Disposable Reinforced Surgical Gown:
Surgical gown is made from high quality composite material. It is breathable, water resistant, and anti-static.
Color: Blue
Size: L/XL or custmozied
Weight: 41gsm
Fabric Type: SMS
Samples Free samples for 3-5 working days
Features Long sleeve, Round neck(Velcro), Rib cuff, double waist tie, Ultrasonic seam
Application Used to prevent infection between patients and medical staff during procedures and other traumatic examinations
Reinforced Disposable Gown,Level 3 Surgical Gown,Disposable Reinforced Gown,Non Sterile Surgical Gowns
Suzhou JaneE Medical Technology Co., Ltd. , https://www.janeemedical.com